OptimizeRx Corporation
OPRX
$7.77
$0.628.67%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 30.48% | 36.14% | 51.43% | 44.34% | 8.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.48% | 36.14% | 51.43% | 44.34% | 8.26% |
| Cost of Revenue | 20.38% | 18.61% | 34.40% | 46.22% | 15.29% |
| Gross Profit | 37.21% | 49.57% | 64.19% | 43.25% | 4.03% |
| SG&A Expenses | 4.18% | 17.78% | 15.21% | 17.77% | 1.77% |
| Depreciation & Amortization | 134.48% | 130.75% | 129.96% | 120.42% | -9.46% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.56% | 20.86% | 23.19% | 30.04% | 5.53% |
| Operating Income | 69.80% | 22.69% | 28.80% | 295.19% | 5.42% |
| Income Before Tax | -246.98% | -23.45% | -2.45% | -3,503.22% | 17.36% |
| Income Tax Expenses | -- | -3,396.97% | -- | -- | -- |
| Earnings from Continuing Operations | -218.46% | 3.68% | -7.83% | -1,171.15% | 17.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -218.46% | 3.68% | -7.83% | -1,171.15% | 17.36% |
| EBIT | 69.80% | 22.69% | 28.80% | 295.19% | 5.42% |
| EBITDA | 95.81% | 36.97% | 38.79% | 3,901.05% | 10.59% |
| EPS Basic | -189.14% | 10.37% | -1.44% | -1,126.32% | 10.68% |
| Normalized Basic EPS | 22.30% | -14.89% | 3.59% | 351.26% | 10.71% |
| EPS Diluted | -190.36% | 10.17% | -1.52% | -1,167.89% | 10.68% |
| Normalized Diluted EPS | 22.30% | -14.89% | 3.59% | 351.26% | 10.71% |
| Average Basic Shares Outstanding | 10.13% | 7.45% | 6.29% | 3.64% | -7.47% |
| Average Diluted Shares Outstanding | 10.13% | 7.45% | 6.29% | 3.64% | -7.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
